3U19AG010483-26S8 |
2020 |
$8741293 |
None |
Alzheimer's Disease Cooperative Study |
FELDMAN, HOWARD |
3U19AG010483-26S7 |
2019 |
$2365884 |
7824 |
ADMINISTRATIVE CORE |
AISEN, PAUL S |
3U19AG010483-26S7 |
2019 |
$458415 |
7825 |
BIOSTAT CORE |
THOMAS, RON G |
3U19AG010483-26S7 |
2019 |
$1647744 |
7826 |
INFORMATICS CORE |
AISEN, PAUL S |
3U19AG010483-26S7 |
2019 |
$1497340 |
7827 |
CLINICAL OPERATIONS CORE |
AISEN, PAUL S |
3U19AG010483-26S7 |
2019 |
$1567987 |
7828 |
MED & SAFETY CORE |
RAMAN, REMA |
3U19AG010483-26S7 |
2019 |
$223751 |
7830 |
BIOMARKER CORE |
RISSMAN, ROBERT A |
3U19AG010483-26S7 |
2019 |
$178631 |
7831 |
IMAGING CORE |
BREWER, JAMES A |
3U19AG010483-26S7 |
2019 |
$863645 |
7835 |
CSF SAMPLING STUDY |
GALASKO, DOUGLAS R |
3U19AG010483-26S6 |
2018 |
$100000 |
None |
Alzheimers Disease Cooperative Study |
FELDMAN, HOWARD |
5U19AG010483-26 |
2017 |
$261995 |
7826 |
INFORMATICS CORE |
Aisen, Paul |
5U19AG010483-26 |
2017 |
$1032084 |
7828 |
MED & SAFETY CORE |
RAMAN, REMA |
5U19AG010483-26 |
2017 |
$478747 |
7834 |
PRAZOSIN FOR AGITATION IN Alzheimer's DISEASE |
PESKIND, ELAINE R. |
5U19AG010483-26 |
2017 |
$231811 |
7829 |
RECRUITMENT CORE |
SANO, MARY |
5U19AG010483-26 |
2017 |
$2688971 |
7832 |
ANTI-AMYLOID TREATMENT IN ASYMPTOMATIC Alzheimer's DISEASE |
SPERLING, REISA A. |
5U19AG010483-26 |
2017 |
$1817862 |
7824 |
ADMINISTRATIVE CORE |
Aisen, Paul |
5U19AG010483-26 |
2017 |
$7799987 |
None |
ALZHEIMER'S DISEASE COOPERATIVE STUDY (ADCS) |
FELDMAN, HOWARD |
3U19AG010483-26S1 |
2017 |
$100065 |
None |
ALZHEIMER'S DISEASE COOPERATIVE STUDY (ADCS) |
FELDMAN, HOWARD |
3U19AG010483-26S2 |
2017 |
$100000 |
None |
ALZHEIMER'S DISEASE COOPERATIVE STUDY (ADCS) |
FELDMAN, HOWARD |
3U19AG010483-26S5 |
2017 |
$2206643 |
None |
ALZHEIMER'S DISEASE COOPERATIVE STUDY (ADCS) |
FELDMAN, HOWARD |
3U19AG010483-26S4 |
2017 |
$3723659 |
None |
ALZHEIMER'S DISEASE COOPERATIVE STUDY (ADCS) |
FELDMAN, HOWARD |
3U19AG010483-26S3 |
2017 |
$2819262 |
None |
ALZHEIMER'S DISEASE COOPERATIVE STUDY (ADCS) |
FELDMAN, HOWARD |
5U19AG010483-26 |
2017 |
$221844 |
7830 |
BIOMARKER CORE |
RISSMAN, ROBERT A |
5U19AG010483-26 |
2017 |
$202838 |
7825 |
BIOSTAT CORE |
THOMAS, RON G |
5U19AG010483-26 |
2017 |
$501123 |
7827 |
CLINICAL OPERATIONS CORE |
Aisen, Paul |
5U19AG010483-26 |
2017 |
$362712 |
7831 |
IMAGING CORE |
BREWER, JAMES A |
4U19AG010483-25 |
2016 |
$1376601 |
7834 |
PRAZOSIN FOR AGITATION IN ALZHEIMER'S DISEASE |
PESKIND, ELAINE R. |
4U19AG010483-25 |
2016 |
$251698 |
7829 |
RECRUITMENT CORE |
SANO, MARY |
4U19AG010483-25 |
2016 |
$1812321 |
7824 |
ADMINISTRATIVE CORE |
Aisen, Paul |
4U19AG010483-25 |
2016 |
$10006406 |
None |
ALZHEIMER'S DISEASE COOPERATIVE STUDY (ADCS) |
FELDMAN, HOWARD |
3U19AG010483-25S2 |
2016 |
$100000 |
None |
ALZHEIMER'S DISEASE COOPERATIVE STUDY (ADCS) |
FELDMAN, HOWARD |
3U19AG010483-25S1 |
2016 |
$126000 |
None |
ALZHEIMER'S DISEASE COOPERATIVE STUDY (ADCS) |
FELDMAN, HOWARD |
3U19AG010483-25S3 |
2016 |
$137619 |
None |
ALZHEIMER'S DISEASE COOPERATIVE STUDY (ADCS) |
FELDMAN, HOWARD |
3U19AG010483-25S4 |
2016 |
$100000 |
None |
ALZHEIMER'S DISEASE COOPERATIVE STUDY (ADCS) |
FELDMAN, HOWARD |
4U19AG010483-25 |
2016 |
$3286257 |
7832 |
ANTI-AMYLOID TREATMENT IN ASYMPTOMATIC Alzheimer's DISEASE |
SPERLING, REISA A. |
4U19AG010483-25 |
2016 |
$220796 |
7830 |
BIOMARKER CORE |
RISSMAN, ROBERT A |
4U19AG010483-25 |
2016 |
$207468 |
7825 |
BIOSTAT CORE |
THOMAS, RON G |
4U19AG010483-25 |
2016 |
$501124 |
7827 |
CLINICAL OPERATIONS CORE |
Aisen, Paul |
4U19AG010483-25 |
2016 |
$697720 |
7833 |
EXERCISE TRIAL |
BAKER, LAURA D. |
4U19AG010483-25 |
2016 |
$361001 |
7831 |
IMAGING CORE |
BREWER, JAMES A |
4U19AG010483-25 |
2016 |
$261995 |
7826 |
INFORMATICS CORE |
Aisen, Paul |
4U19AG010483-25 |
2016 |
$1029425 |
7828 |
MED & SAFETY CORE |
RAMAN, REMA |
5U19AG010483-24 |
2015 |
$1191547 |
7834 |
PRAZOSIN FOR AGITATION IN Alzheimer's DISEASE |
PESKIND, ELAINE R. |
5U19AG010483-24 |
2015 |
$244148 |
7829 |
RECRUITMENT CORE |
SANO, MARY |
5U19AG010483-24 |
2015 |
$1744623 |
7824 |
ADMINISTRATIVE CORE |
Aisen, Paul |
5U19AG010483-24 |
2015 |
$11393316 |
None |
ALZHEIMER'S DISEASE COOPERATIVE STUDY (ADCS) |
MOBLEY, WILLIAM C |
3U19AG010483-24S1 |
2015 |
$99639 |
None |
ALZHEIMER'S DISEASE COOPERATIVE STUDY (ADCS) |
MOBLEY, WILLIAM C |
5U19AG010483-24 |
2015 |
$3987763 |
7832 |
ANTI-AMYLOID TREATMENT IN ASYMPTOMATIC Alzheimer's DISEASE |
SPERLING, REISA A. |
5U19AG010483-24 |
2015 |
$225185 |
7830 |
BIOMARKER CORE |
RISSMAN, ROBERT A |
5U19AG010483-24 |
2015 |
$196708 |
7825 |
BIOSTAT CORE |
THOMAS, RON G |
5U19AG010483-24 |
2015 |
$486091 |
7827 |
CLINICAL OPERATIONS CORE |
Aisen, Paul |
5U19AG010483-24 |
2015 |
$270890 |
7835 |
CSF SAMPLING STUDY |
GALASKO, DOUGLAS R |
5U19AG010483-24 |
2015 |
$1445276 |
7833 |
EXERCISE TRIAL |
BAKER, LAURA D. |
5U19AG010483-24 |
2015 |
$346282 |
7831 |
IMAGING CORE |
BREWER, JAMES A |
5U19AG010483-24 |
2015 |
$262290 |
7826 |
INFORMATICS CORE |
Aisen, Paul |
5U19AG010483-24 |
2015 |
$992513 |
7828 |
MED & SAFETY CORE |
RAMAN, REMA |
5U19AG010483-23 |
2014 |
$134046 |
7831 |
IMAGING CORE |
BREWER, JAMES A |
5U19AG010483-23 |
2014 |
$261996 |
7826 |
INFORMATICS CORE |
Aisen, Paul |
5U19AG010483-23 |
2014 |
$1020794 |
7828 |
MED & SAFETY CORE |
RAMAN, REMA |
5U19AG010483-23 |
2014 |
$251697 |
7829 |
RECRUITMENT CORE |
SANO, MARY |
5U19AG010483-23 |
2014 |
$1793520 |
7824 |
ADMINISTRATIVE CORE |
Aisen, Paul |
5U19AG010483-23 |
2014 |
$12480297 |
None |
ALZHEIMER'S DISEASE COOPERATIVE STUDY (ADCS) |
Aisen, Paul |
5U19AG010483-23 |
2014 |
$5116455 |
7832 |
ANTI-AMYLOID TREATMENT IN ASYMPTOMATIC Alzheimer's DISEASE |
SPERLING, REISA A. |
5U19AG010483-23 |
2014 |
$216991 |
7830 |
BIOMARKER CORE |
RISSMAN, ROBERT A |
5U19AG010483-23 |
2014 |
$202793 |
7825 |
BIOSTAT CORE |
THOMAS, RON G |
5U19AG010483-23 |
2014 |
$501125 |
7827 |
CLINICAL OPERATIONS CORE |
Aisen, Paul |
5U19AG010483-23 |
2014 |
$572234 |
7835 |
CSF SAMPLING STUDY |
GALASKO, DOUGLAS R |
5U19AG010483-23 |
2014 |
$2408646 |
7833 |
EXERCISE TRIAL |
BAKER, LAURA D. |
2U19AG010483-22 |
2013 |
$213886 |
None |
BIOSTAT CORE |
THOMAS, RON G |
2U19AG010483-22 |
2013 |
$517721 |
None |
CLINICAL OPERATIONS CORE |
Aisen, Paul |
2U19AG010483-22 |
2013 |
$1644735 |
7833 |
EXERCISE TRIAL |
BAKER, LAURA D. |
2U19AG010483-22 |
2013 |
$150566 |
None |
IMAGING CORE |
BREWER, JAMES A |
2U19AG010483-22 |
2013 |
$311900 |
None |
INFORMATICS CORE |
Aisen, Paul |
2U19AG010483-22 |
2013 |
$1159779 |
None |
MED & SAFETY CORE |
RAMAN, REMA |
2U19AG010483-22 |
2013 |
$260033 |
None |
RECRUITMENT CORE |
SANO, MARY |
2U19AG010483-22 |
2013 |
$4621257 |
7832 |
ANTI-AMYLOID TREATMENT IN ASYMPTOMATIC Alzheimer's DISEASE |
SPERLING, REISA A. |
2U19AG010483-22 |
2013 |
$2125707 |
None |
ADMINISTRATIVE CORE |
Aisen, Paul |
2U19AG010483-22 |
2013 |
$282984 |
None |
BIOMARKER CORE |
RISSMAN, ROBERT A |